Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Janet William

Nurse Practitioner Cerritos, CA Nurse Practitioner

NPI 1821505587 CMS profile 11093730

18000 Studebaker Rd Ste 800, Cerritos, CA 90703

Open in the dashboard

General payments

$23,383

989 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janet William of Cerritos, CA is reported in the CMS Open Payments database as having received $23,383 across 989 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,284 217
2024 General $5,490 221
2023 General $4,516 198
2022 General $4,438 182
2021 General $3,655 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janet William
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Janet William were reported at $5,284. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Janet William Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,655 $135 $40–$426 $132
2022 $4,438 $152 $48–$470 $149
2023 $4,516 $166 $54–$529 $160
2024 $5,490 $173 $55–$556 $164
2025 $5,284 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $3,169 112 payments
  2. Merck Sharp & Dohme Corporation $1,644 69 payments
  3. Janssen Biotech, Inc. $1,148 41 payments
  4. Amgen Inc. $1,031 48 payments
  5. Seattle Genetics, Inc. $1,015 34 payments
  6. Incyte Corporation $981 35 payments
  7. AstraZeneca Pharmaceuticals LP $877 38 payments
  8. Celgene Corporation $870 39 payments
  9. Astellas Pharma US Inc $819 30 payments
  10. E.R. Squibb & Sons, L.L.C. $698 47 payments
  11. Other $11,131 496 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,471 954 payments
  2. Education $1,480 19 payments
  3. Long term medical supply or device loan $1,432 16 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,709 46 payments
  2. KEYTRUDA $1,606 67 payments
  3. IMBRUVICA $617 21 payments
  4. LIBTAYO $609 28 payments
  5. Lenvima $607 27 payments
  6. DARZALEX $523 17 payments
  7. ENHERTU $521 22 payments
  8. MONJUVI $497 19 payments
  9. JAKAFI $490 21 payments
  10. OPDIVO $458 29 payments
  11. Other $18,402 891 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

325

Median for Nurse Practitioner: 389

Drug cost

$18,535

Median for Nurse Practitioner: $21,885

Branded share of claims

47.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $8,357
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 78 $2,688
Fentanyl Generic 21 $2,073
Ondansetron Hcl Generic 17 $1,287
Oxycodone Hcl Generic 19 $940
Anastrozole Generic 58 $940
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $613
Morphine Sulfate Er Morphine Sulfate Brand 11 $481
Ondansetron Odt Ondansetron Brand 22 $319
Hydroxyurea Generic 20 $313

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 76 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
$978 — —
KEYTRUDA
$359 — —
ENHERTU
$286 — —
Lenvima
$157 — —
OPDIVO
$156 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 76 with Patron

Records

989 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record